These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 17964663)

  • 21. Mechanisms of costimulation.
    Sharpe AH
    Immunol Rev; 2009 May; 229(1):5-11. PubMed ID: 19426211
    [No Abstract]   [Full Text] [Related]  

  • 22. Allelic variant in CTLA4 alters T cell phosphorylation patterns.
    Maier LM; Anderson DE; De Jager PL; Wicker LS; Hafler DA
    Proc Natl Acad Sci U S A; 2007 Nov; 104(47):18607-12. PubMed ID: 18000051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-CD28 costimulatory molecules present in T cell rafts induce T cell costimulation by enhancing the association of TCR with rafts.
    Yashiro-Ohtani Y; Zhou XY; Toyo-Oka K; Tai XG; Park CS; Hamaoka T; Abe R; Miyake K; Fujiwara H
    J Immunol; 2000 Feb; 164(3):1251-9. PubMed ID: 10640738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression.
    Carreno BM; Bennett F; Chau TA; Ling V; Luxenberg D; Jussif J; Baroja ML; Madrenas J
    J Immunol; 2000 Aug; 165(3):1352-6. PubMed ID: 10903737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells.
    Krummel MF; Allison JP
    J Exp Med; 1996 Jun; 183(6):2533-40. PubMed ID: 8676074
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis.
    Melichar B; Nash MA; Lenzi R; Platsoucas CD; Freedman RS
    Clin Exp Immunol; 2000 Jan; 119(1):19-27. PubMed ID: 10606960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation.
    Vandenborre K; Van Gool SW; Kasran A; Ceuppens JL; Boogaerts MA; Vandenberghe P
    Immunology; 1999 Nov; 98(3):413-21. PubMed ID: 10583602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Negative regulation of T cell receptor-lipid raft interaction by cytotoxic T lymphocyte-associated antigen 4.
    Chikuma S; Imboden JB; Bluestone JA
    J Exp Med; 2003 Jan; 197(1):129-35. PubMed ID: 12515820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disparate effects of phorbol esters, CD3 and the costimulatory receptors CD2 and CD28 on RANTES secretion by human T lymphocytes.
    Sotsios Y; Blair PJ; Westwick J; Ward SG
    Immunology; 2000 Sep; 101(1):30-7. PubMed ID: 11012750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chimeric co-stimulatory molecules that selectively act through CD28 or CTLA-4 on human T cells.
    Lazetic S; Leong SR; Chang JC; Ong R; Dawes G; Punnonen J
    J Biol Chem; 2002 Oct; 277(41):38660-8. PubMed ID: 12167647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes.
    Linsley PS; Greene JL; Tan P; Bradshaw J; Ledbetter JA; Anasetti C; Damle NK
    J Exp Med; 1992 Dec; 176(6):1595-604. PubMed ID: 1334116
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CTLA-4 ligation blocks CD28-dependent T cell activation.
    Walunas TL; Bakker CY; Bluestone JA
    J Exp Med; 1996 Jun; 183(6):2541-50. PubMed ID: 8676075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD28 and CTLA-4 coreceptor expression and signal transduction.
    Rudd CE; Taylor A; Schneider H
    Immunol Rev; 2009 May; 229(1):12-26. PubMed ID: 19426212
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytotoxic T lymphocyte antigen 4 (CTLA-4) engagement delivers an inhibitory signal through the membrane-proximal region in the absence of the tyrosine motif in the cytoplasmic tail.
    Nakaseko C; Miyatake S; Iida T; Hara S; Abe R; Ohno H; Saito Y; Saito T
    J Exp Med; 1999 Sep; 190(6):765-74. PubMed ID: 10499915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD28, CTLA-4 and their ligands: who does what and to whom?
    Sansom DM
    Immunology; 2000 Oct; 101(2):169-77. PubMed ID: 11012769
    [No Abstract]   [Full Text] [Related]  

  • 36. Ginsenoside compound K suppresses the abnormal activation of T lymphocytes in mice with collagen-induced arthritis.
    Liu KK; Wang QT; Yang SM; Chen JY; Wu HX; Wei W
    Acta Pharmacol Sin; 2014 May; 35(5):599-612. PubMed ID: 24727939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Yin and Yang of T cell costimulation.
    Allison JP; Krummel MF
    Science; 1995 Nov; 270(5238):932-3. PubMed ID: 7481795
    [No Abstract]   [Full Text] [Related]  

  • 38. CTLA-4--the costimulatory molecule that doesn't: regulation of T-cell responses by inhibition.
    Chambers CA; Allison JP
    Cold Spring Harb Symp Quant Biol; 1999; 64():303-12. PubMed ID: 11232300
    [No Abstract]   [Full Text] [Related]  

  • 39. B7-CTLA4 interaction promotes cognate destruction of tumor cells by cytotoxic T lymphocytes in vivo.
    Bai XF; Liu J; May KF; Guo Y; Zheng P; Liu Y
    Blood; 2002 Apr; 99(8):2880-9. PubMed ID: 11929778
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contributions of the T cell receptor-associated CD3gamma-ITAM to thymocyte selection.
    Haks MC; Pépin E; van den Brakel JH; Smeele SA; Belkowski SM; Kessels HW; Krimpenfort P; Kruisbeek AM
    J Exp Med; 2002 Jul; 196(1):1-13. PubMed ID: 12093866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.